Cathay Biotech 凯赛生物
8 significant filings since 30 May 2026: 1 on litigation, 4 on equity incentive and 1 on guarantee or financial assistance, and 2 other kinds. The latest, on 24 Sep 2026: 上海市锦天城律师事务所关于上海凯赛生物技术股份有限公司2025年员工持股计划预留份额购买价格调整及分配的法律意见书.
自 30 May 2026 起有 8 份重大公告：litigation 1 份、equity incentive 4 份、guarantee or financial assistance 1 份，另有 2 类。最新一份（24 Sep 2026）：上海市锦天城律师事务所关于上海凯赛生物技术股份有限公司2025年员工持股计划预留份额购买价格调整及分配的法律意见书。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 2 Mar 2022 | 国金证券 | 陈屹,杨翼荥,王明辉 | Buy 买入 | ▼ | Outperform 增持 |
| 20 Aug 2021 | 国金证券 | 杨翼荥 | Outperform 增持 | ▲ | Buy 买入 |
| 20 Apr 2021 | 国金证券 | 杨翼荥 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 华鑫证券 | 卢昊,高铭谦 | Buy 买入 | 7 May 2026 | 1 | — |
| 华安证券 | 王强峰,刘天其 | Buy 买入 | 11 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 2 reports. 每行为该券商近十二个月的最新研报；2 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。